Full View

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
被引用次数：12 相关文章

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan

JWC Chang, CY Huang, YF Fang… - Thoracic …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the
standard treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR …

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.

JW Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2022 - europepmc.org
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the
standard treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR …
[HTML] nih.gov

[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from …

JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - search.proquest.com
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …

[引用][C] Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan

JWC Chang, CY Huang, YF Fang, CF Chang, CT Yang… - 2022 - europepmc.org
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the
standard treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR …